What is the recommended dose of Levipil (levetiracetam) for a 13-year-old child weighing 48 kg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Levetiracetam (Levipil) Dosing for a 13-Year-Old Child Weighing 48 kg

For a 13-year-old child weighing 48 kg, the appropriate dose of Levipil (levetiracetam) is 1500 mg/day, administered as 750 mg twice daily.

Dosage Calculation Based on Weight

Levetiracetam dosing for children is primarily determined by weight, with FDA-approved guidelines providing clear recommendations:

  • For children weighing >40 kg: 1500 mg/day (750 mg tablet BID) as the target dose for adjunctive therapy 1
  • This dosing is appropriate for children aged 4-16 years with partial onset seizures, which aligns with this patient's age group

Dosing Protocol

Initial Dosing

  • Start with 20 mg/kg/day in 2 divided doses (10 mg/kg BID)
  • For a 48 kg child, this equals approximately 960 mg/day (480 mg BID)

Titration

  • Increase dose every 2 weeks by increments of 20 mg/kg/day
  • Target maintenance dose is 60 mg/kg/day (30 mg/kg BID)
  • For a 48 kg child, the maximum target dose would be 2880 mg/day
  • However, the FDA-approved tablet dosing guide recommends 1500 mg/day for children >40 kg during titration to 60 mg/kg/day 1

Administration

  • Levetiracetam can be given with or without food
  • For a 48 kg child, use 750 mg tablets twice daily
  • Ensure whole tablets are administered

Evidence-Based Considerations

Efficacy

  • Clinical trials have shown that levetiracetam is effective as adjunctive therapy in children with refractory epilepsy
  • Studies demonstrate 51.5% of children achieve >50% seizure reduction after 26 weeks of treatment 2
  • Approximately 27.3% of children become seizure-free for at least 4 weeks 2

Pharmacokinetics in Children

  • Children have a 30-40% higher clearance rate compared to adults 3
  • The half-life of levetiracetam in children is approximately 6.0 ± 1.1 hours 3
  • A maintenance dose equivalent to 130-140% of the usual adult maintenance dose on a weight-normalized level is recommended 3

Monitoring and Safety Considerations

Common Side Effects

  • Most common adverse effects include:
    • Hyperactivity (48.5%)
    • Somnolence (36.4%)
    • Irritability (33.3%)
    • Aggressive behavior (27.3%) 2
  • Most side effects are mild in severity

Monitoring Parameters

  • Regular assessment of seizure frequency and severity
  • Monitoring for behavioral changes, particularly irritability or aggression
  • No specific laboratory monitoring is required, though baseline complete blood count may be considered 4

Important Clinical Caveats

  • If the child cannot tolerate the target dose of 60 mg/kg/day, the dose may be reduced
  • In clinical trials, the mean daily dose was 52 mg/kg 1
  • Retention rate is approximately 70% after 26 weeks of therapy 2
  • Levetiracetam has shown efficacy in both partial and primary generalized seizures, with better response in partial seizures 2
  • The recommended dose may need adjustment based on clinical response and tolerability

By following these dosing guidelines, the child should receive appropriate therapeutic levels of levetiracetam while minimizing the risk of adverse effects.

References

Research

Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 2008

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.